Deutsche Bank Raises Amedisys (NASDAQ:AMED) Price Target to $260.00

Amedisys (NASDAQ:AMED) had its target price lifted by Deutsche Bank from $220.00 to $260.00 in a research note published on Thursday morning, The Fly reports. Deutsche Bank currently has a buy rating on the health services provider’s stock.

Several other analysts have also recently weighed in on AMED. Zacks Investment Research upgraded shares of Amedisys from a hold rating to a buy rating and set a $193.00 price objective for the company in a research note on Friday, May 1st. Royal Bank of Canada reiterated a buy rating and issued a $218.00 price target on shares of Amedisys in a research report on Sunday, May 10th. BidaskClub raised Amedisys from a hold rating to a buy rating in a research report on Saturday, July 18th. Jefferies Financial Group lifted their price objective on Amedisys from $225.00 to $250.00 and gave the company a buy rating in a report on Wednesday. Finally, Raymond James upped their target price on Amedisys from $210.00 to $255.00 and gave the company an outperform rating in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of Buy and a consensus target price of $215.67.

Shares of NASDAQ AMED opened at $234.16 on Thursday. The firm has a market cap of $7.58 billion, a P/E ratio of 60.66, a price-to-earnings-growth ratio of 3.44 and a beta of 0.95. The company has a current ratio of 1.02, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. Amedisys has a 1-year low of $121.00 and a 1-year high of $237.28. The business’s 50 day moving average is $202.10 and its 200-day moving average is $187.33.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Tuesday, July 28th. The health services provider reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.53. Amedisys had a return on equity of 22.41% and a net margin of 6.50%. The firm had revenue of $485.06 million for the quarter, compared to analyst estimates of $468.38 million. During the same period in the prior year, the firm posted $1.21 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Analysts forecast that Amedisys will post 4.84 EPS for the current year.

In related news, insider David L. Kemmerly sold 23,437 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $175.32, for a total transaction of $4,108,974.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce D. Perkins acquired 2,000 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The stock was bought at an average cost of $167.48 per share, with a total value of $334,960.00. Following the purchase, the director now owns 28,236 shares in the company, valued at $4,728,965.28. The disclosure for this purchase can be found here. In the last three months, insiders have sold 38,693 shares of company stock valued at $6,882,126. Insiders own 2.90% of the company’s stock.

Several large investors have recently made changes to their positions in AMED. Shilanski & Associates Inc. lifted its stake in shares of Amedisys by 1.1% in the 1st quarter. Shilanski & Associates Inc. now owns 4,868 shares of the health services provider’s stock valued at $893,000 after acquiring an additional 54 shares during the last quarter. NEXT Financial Group Inc increased its holdings in Amedisys by 6.7% in the 2nd quarter. NEXT Financial Group Inc now owns 1,034 shares of the health services provider’s stock worth $205,000 after purchasing an additional 65 shares in the last quarter. National Asset Management Inc. raised its position in Amedisys by 2.9% in the first quarter. National Asset Management Inc. now owns 2,513 shares of the health services provider’s stock valued at $462,000 after purchasing an additional 72 shares during the last quarter. Alpine Woods Capital Investors LLC boosted its stake in shares of Amedisys by 0.6% during the first quarter. Alpine Woods Capital Investors LLC now owns 16,058 shares of the health services provider’s stock valued at $2,947,000 after purchasing an additional 100 shares in the last quarter. Finally, First Citizens Bank & Trust Co. grew its holdings in shares of Amedisys by 7.8% during the first quarter. First Citizens Bank & Trust Co. now owns 1,395 shares of the health services provider’s stock worth $256,000 after purchasing an additional 101 shares during the last quarter. Institutional investors own 88.31% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Read More: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

The Fly

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.